Large disparities in life expectancy observed, which grew over time, especially during the first two years of COVID-19
AHA: Initial Catheter Ablation Beneficial for Ventricular Tachycardia
Initial strategy of catheter ablation leads to lower risk for composite primary end point versus antiarrhythmic drug therapy
AHA: Tirzepatide Beneficial for Heart Failure With Preserved EF, Obesity
Lower risk for composite of death from cardiovascular causes or worsening heart failure seen with tirzepatide versus placebo
AHA: Half of U.S. Adults Are Eligible for Treatment With Semaglutide
More than 39 million U.S. adults qualify for indications other than weight management alone